Background: Glucose-lowering treatments are used during pregnancy to reduce the risk for complications in the mother and offspring, yet treatment targets have not been established.
increased insulin resistance and hyperglycemia in the fetus (1, 2), which can lead to future obesity and diabetes (3, 4) . The increasing incidence of pregnant women with GDM and T2DM as part of the ongoing epidemic of obesity (5) highlights the importance of managing hyperglycemia during pregnancy from a clinical and public health perspective.
Although glycemic control in GDM (6, 7) and preexisting diabetes (8) has been found to be beneficial, there are no clearly established glucose targets (9, 10) . Furthermore, achieving adequate glucose control during pregnancy continues to be a great challenge for endocrinologists and obstetricians (9) and requires a multidisciplinary and individualized approach that includes nutritional, physical activity, and pharmacologic interventions. Tight control may also be associated with more hospital visits, increased maternal mortality due to severe hypoglycemia as well as fetal hypoglycemia, exacerbation of diabetic retinopathy in women with T1DM (11, 12) , and intrauterine growth restriction (13) . It is also extremely important to realize that the treatment burden of interventions aimed at achieving tight glucose control may overwhelm patients (14) and have its own inherent adverse effects. Thus, establishing evidence-based glucose targets that take into account concerns about benefit, costs, and harm is needed.
An expert panel from The Endocrine Society was charged with developing a clinical practice guideline for the management of hyperglycemia during pregnancy. To aid in the development of the Society guidelines, we conducted this systematic review and meta-analysis.
Materials and Methods
Search and analysis methods, eligibility criteria, and the outcomes of interest were specified in advance in a protocol developed by study investigators with input from the expert panel from The Endocrine Society.
Eligibility criteria
We included randomized controlled trials (RCTs) and observational studies that enrolled pregnant women with T1DM, T2DM, and GDM in pregnancy and evaluated the association between different blood glucose targets achieved during pregnancy and maternal and fetal outcomes.
Search methods
An expert reference librarian (L.J.P.), following the protocol, designed and conducted electronic search strategies (Supplemental Table 1 , published on The Endocrine Society's Journals Online website at http://jcem.endojournals.org) with input from study investigators with expertise in conducting systematic reviews (M.H.M. and V.M.M.). We searched electronic databases Medline, EMBASE and Cochrane Library (through the OVID interface), Web of Science, Scopus, PsycInfo, and CINAHL, from inception through May 2011. To identify additional candidate studies, 2 reviewers (G.J.P. and J.P.D.) reviewed the reference lists of the eligible primary studies, narrative reviews, and systematic reviews and queried experts.
Selection of studies
Two reviewers working independently considered the potential eligibility of each of the abstracts and titles that resulted from the search strategy. Disagreements in the abstract and title screening were automatically considered eligible for the full text review. Eligible studies were reviewed in full text versions (all available versions of each study). We achieved a substantial agreement ( ϭ 0.80) during full text screening phase.
Data extraction and management
Using a standardized, piloted, and web-based data extraction form and working in duplicates, we abstracted the following descriptive data from each study: full description of participants enrolled (eg, age, ethnicity, and type of diabetes), interventions received, monitoring for efficacy and for adherence to the treatment, outcomes, and source of funding.
The outcomes of interest were 1) macrosomia (birth weight Ն4000 g); 2) other fetal outcomes such as large for gestational age (LGA), neonatal mortality, brachial plexus injury, clavicular fracture, admission to a neonatal intensive care unit (ICU), hypoglycemia requiring treatment, hyperbilirubinemia requiring treatment or admission to an ICU, and respiratory distress syndrome; and 3) maternal outcomes such as maternal mortality, preeclampsia, and gestational hypertension.
Author contact
When data were not available or unclear from the published papers, repeated efforts were performed to contact the authors. We contacted the corresponding author of each study twice within 2 weeks via email or, when email was not available, by phone or mail. After author contact, studies with data insufficient for analysis were excluded.
Assessment of risk of bias in included studies
To assess the methodological quality of the included RCTs we used the Cochrane Collaboration's Risk of Bias assessment tool to evaluate randomization performance and methods, allocation concealment, baseline imbalances, extent of blinding (patients, caregivers, data collectors, outcome assessors, and data analysts), rate of loss to follow-up, and monitoring of adherence to the follow-up and its efficiency. For the observational studies, the Newcastle-Ottawa scale was used to evaluate how the groups were selected, the comparability between them, whether there was adequate follow-up, and how outcomes/exposures were ascertained.
Statistical analysis
We pooled the effect size as odds ratio (OR) and 95% confidence interval (CI) across the included studies. The DerSimonian and Laird random-effects methods were adopted, whereas the heterogeneity was estimated using the MantelHaenszel model (15) . Random-effects meta-regression models were constructed after adjusting for diabetes type, trimester, diabetes treatment, and body mass index (BMI), whenever possible.
Heterogeneity across individual studies was assessed using the Cochran's Q statistical test. We adopted a more conservative criterion of P Ͻ .10 to suggest heterogeneity. We planned to assess for publication bias using the Egger regression asymmetry test and visual inspection using funnel plots (16) . However, evaluation of publication bias was not feasible due to significant heterogeneity between the included studies (17) . We explored the possibility of reporting bias by assessing the proportion of studies reporting the levels of exposure (target glucose level) and outcomes of interest of the overall number of studies; a low proportion suggests reporting bias (18) . All meta-analyses were conducted using STATA version 12 software (StataCorp).
Subgroups analysis
We determined several a priori hypotheses to explore subgroup interactions and give a potential explanation for heterogeneity. Subgroup analysis was based on diabetes type (T1DM, T2DM, or GDM) and trimester (first, second, or third). We planned to conduct a test of interaction (19) to evaluate the significance of subgroup analyses and potential correlation between subgroups and the pooled effect size.
Results

Search results and study description
The literature search identified 1536 potentially eligible citations, of which 34 original studies met the eligibility criteria (15 RCTs, 18 cohort studies, and 1 case-control study) (Figure 1) . No unpublished studies were identified.
The included studies (Supplemental Table 2 ) enrolled 9433 women of mean age 31 (range, 15-44) years, with different types of diabetes during pregnancy (22 studies of GDM, 5 of T1DM, and 1 of T2DM; and 6 studies evaluated mixed types of diabetes). Included studies were heterogeneous in terms of the intervention used for glycemic control (eg, lifestyle, insulin, or oral agents) and the criteria used for diagnosing GDM.
Thirty of the included studies reported the association of outcomes with fasting blood glucose (FBG), 20 studies with 2-hour postprandial glucose, 9 studies with 1-hour postprandial glucose, and 9 studies with preprandial glucose. Most of the studies reported achieved mean glucose as opposed to targeted mean glucose. Only 8 of the included studies reported the prepregnancy baseline BMI of the evaluated population.
Author contact
We attempted to contact all the authors of the included studies for additional information not reported in the published manuscript and 1 author to clarify published data. We received 7 answers; only 2 authors were able to provide the required information.
Quality assessment
The methodological quality assessment of the included studies is presented in Supplemental Table 3 . Most studies were at low to moderate risk of bias. Observational studies for the most part failed to report matching participants based on clinical characteristics or adjusting their results accordingly. There was evidence suggestive of reporting bias manifested by the small proportion of studies reporting all the outcomes and tests typically considered important and obtainable (18) .
Outcomes of interest
Glucose measures and macrosomia rate
In a meta-regression model that controlled for intervention, diabetes type, and trimester, we compared different cutoff points for each glucose measure. Only an FBG Ͻ90 mg/dL was associated with a protective effect on the development of macrosomia (OR ϭ 0.53, 95% CI ϭ 0.31-0.90, P ϭ .02). All the other measures did not show a statistically significant association for any of the analyzed cutoff points. These results are summarized in Table 1 . Maternal BMI was reported in only 8 studies. Adjustment for BMI was possible only in the analysis of the 2-hour glucose tolerance test and none of the evaluated cut off points showed a statically significant association (Table 1) .
Subgroup analyses T1DM and T2DM. Women with T1DM were evaluated in 7 studies and T2DM in 4 studies (in these analyses, subgroups of the population of the studies evaluating mixed populations were included). In both cases, there were insufficient data to determine an association between a cutoff point of any of the glucose measures and the outcomes for any trimester. Data are presented in Supplemental  Tables 4 to 9 .
Gestational diabetes mellitus.
Of the included studies, 26 included women with GDM, making this population the most commonly evaluated in this systematic review (in these analyses, subgroups of the population of the studies evaluating mixed populations were included). All of the 26 included studies performed the screening test during the third trimester.
Fasting blood glucose.
In an unadjusted analysis, FBG Ͻ90 mg/dL was associated with the most reduction in the risk of macrosomia (OR ϭ 0.39, 95% CI ϭ 0.29 -0.52, P Ͻ .01), LGA (OR ϭ0.68, 95% CI ϭ 0.53-0.88, P ϭ .01), neonatal hypoglycemia (OR ϭ 0.65, 95% CI ϭ 0.49 -0.85, P ϭ .01), hyperbilirubinemia (OR ϭ 0.63, 95% CI ϭ 0.43-0.90, P ϭ .01), and preeclampsia (OR ϭ 0.47, 95% CI ϭ 0.31-0.72, P ϭ .01) when it was evaluated for the third trimester ( Table 2 ). Considering that usually GDM is diagnosed during 24 to 28 weeks, there was very little information for other trimesters.
Pre-and postprandial measures. Pre-and postprandial measures were reported less often. The analyses for these measures were limited by significant statistical heterogeneity explained by differences in glucose load/meal type and glucose measurement timing in relation to the meal/ load. There was also a very small number of events in these analyses, leading to imprecision. b P values for interaction test are based on ANOVA test (P Ͻ .05 implies statistically significant difference across the subgroups).
Both pre-and postprandial glucose targets were not associated with a clear decreased risk of fetal maternal outcomes. CIs for postprandial ORs were wider, and confidence in these estimates was lower than that for preprandial glucose targets (Table 2) .
There was insufficient information to determine an association between a cutoff point of any of the glucose measures and the outcomes of neonatal mortality, neonatal ICU admission, respiratory distress syndrome, and gestational hypertension during the third trimester.
Discussion
Defining gestational diabetes as well as establishing the goals of treatment for hyperglycemia in pregnancy have been the subject of much controversy. Although treatment of marked hyperglycemia is clearly associated with benefit in improving maternal fetal outcomes, treatment with glucoselowering agents is associated with increased risk of hypoglycemia and exposure to potentially teratogenic agents. Moreover, there is a significant treatment burden associated with such interventions. Balancing these disadvantages against the benefits of treatment is fairly straightforward in the setting of uncontrolled, symptomatic hyperglycemia. The problem that this systematic review seeks to address is to better define the point at which treatment is beneficial, thereby avoiding unnecessary over-or undertreatment.
Main findings
We conducted a systematic review and meta-analysis to establish the optimal glucose target in pregnant women with T1DM, T2DM, and GDM. Evidence showed that FBG Յ90 mg/dL is associated with reduction in the risk of macrosomia, neonatal hypoglycemia, and maternal preeclampsia in GDM during the third trimester (no information available for previous trimesters). Of note, the quality of this evidence is low. For women with T1DM or T2DM before pregnancy, the evidence was inconclusive. Data regarding pre-or postprandial blood glucose targets were sparse, and the quality of such evidence is very low.
The literature is limited by its paucity, heterogeneity (different diagnostic criteria for GDM, different glucose targets, different outcomes of interest, and different study methods), lack of patient-important outcomes, high likelihood of reporting bias, inconsistency in results across studies, and lack of adjustment for maternal BMI.
Limitations and strengths
The strengths of this review are related to the comprehensive nature of the literature search and the measures undertaken to reduce the effect of bias and error: predefined protocol-driven work, duplicate review, and attempts to contact authors for missing data. The body of evidence, on the other hand, has some key limitations. The ideal study design to determine the best glucose threshold would be a randomized trial comparing 2 or more thresholds and their impact on critical patient-important benefits, harms, and inconveniences. Such a study does not exist. This review therefore summarizes studies that can only partly inform the question. In addition, most of the studies evaluated women diagnosed with GDM. Hence, this evidence indirectly informs recommendations to be made in women with T1DM or T2DM. Evidence of potential reporting and publication bias and of inconsistency should markedly reduce the readers' confidence in the pooled estimates reported here.
The estimates reported in this systematic review, despite their limitations, are the best available evidence at the It is clear that the extant evidence is insufficient to do so with confidence. Future observational research must evaluate the role of obesity in the incidence of fetal-maternal outcomes in women with and without GDM. Obesity per se has been associated with pregnancy complications for mother and fetus (20) . This association and the epidemic of obesity even among young fertile women highlight the importance of this question.
Conclusions
Evidence warranting very low confidence in the estimates suggests that a fasting glucose target of Ͻ90 mg/dL is associated with a lower risk of macrosomia and other outcomes of different importance in women with gestational diabetes. Whether these targets can be extrapolated to women with diabetes before pregnancy or whether targets above or below this threshold offer a better benefit/ risk balance remains unclear.
